Accipiolx
Overview
MaxQ AI was a medical diagnostic artificial intelligence (AI) company that developed the Accipio platform, a suite of AI-powered software solutions for radiology. The Accipio platform, including AccipioIx, AccipioDx, and AccipioAx, was designed to provide decision support to healthcare professionals for the rapid assessment of non-contrast head CT scans to identify and prioritize cases of acute intracranial hemorrhage (ICH), stroke, and traumatic brain injury. The company’s solutions leveraged deep learning and machine vision technologies to analyze medical images and patient data, aiming to improve detection, accelerate workflow, and assist physicians in making faster, more accurate diagnoses in acute care settings.
It is important to note that MaxQ AI is a deadpooled company and stopped commercial operations in January 2022.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered intracranial hemorrhage (ICH) detection and prioritization
- Workflow prioritization system (Accipio Ix)
- Slice-level annotation and preview with SliceMap (Accipio Ax)
- Automated analysis of non-contrast head CT images
- Integration with PACS systems and CT scanners (DICOM standard)
- Designed for rapid assessment of stroke, traumatic brain injury, and ICH
- Augmented intelligence for physicians
- Real-time intelligent orchestration (MaxQ Xpress)
- Deep learning and machine vision technologies
- Compatibility with major CT OEMs
Use Cases
- Prioritizing suspected ICH cases in emergency rooms
- Aiding in the diagnosis of stroke and traumatic brain injury
- Enhancing clinical workflow in radiology departments
- Providing decision support for neuroradiology teams
- Rapid assessment in acute care settings for brain bleeds
- Reducing missed intracranial hemorrhage detections
What Physicians Need to Know
Accipiolx is a valuable AI-powered tool for rapid detection and prioritization of intracranial hemorrhage on CT scans, particularly useful in acute care settings. Leverage its seamless integration into PACS to quickly identify and triage critical cases. Pay attention to the SliceMap feature in Accipio Ax for directed review of suspicious areas, which can enhance efficiency. Remember that while AI provides strong support, clinical judgment remains paramount.
Accipiolx offers robust integration capabilities with existing imaging infrastructure (CT, PACS systems) via industry-standard DICOM, supporting both on-premise and cloud deployments. Strategic partnerships with major healthcare technology providers facilitate broader adoption and streamlined implementation within diverse clinical environments.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Not publicly disclosed; typically enterprise/custom pricing for medical devices. — N/A |
| Deployment | On-premise and cloud-capable |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated AccipioIx received 510(k) clearance (K201310) from the U.S. Food and Drug Administration (FDA) on August 7, 2020, as a software workflow tool to aid in prioritizing the clinical assessment of adult non-contrast head CT cases with features suggestive of acute intracranial hemorrhage. It was designed not to alter original series or store protected health information (PHI). |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Radiology |
What the Web Says
Accipio Ix, developed by MaxQ AI, was an AI-powered software designed to assist physicians in prioritizing the clinical assessment of adult non-contrast head CT cases for suspected intracranial hemorrhage (ICH). It received FDA clearance in 2018 and CE Mark approval, aiming to improve the detection and review time of brain bleeds. However, MaxQ AI discontinued the Accipio line of software in January 2022 to shift its focus to non-image-based AI algorithms.
Overall: NegativeStrengths
- Aids in prioritizing patients with suspected intracranial hemorrhage (ICH) for treating physicians.
- Designed to be highly sensitive to the presence of ICH.
- Can be natively integrated into CT and PACS systems using DICOM standards.
- Installable both on-premise and cloud-capable.
- Leverages AI to automatically analyze non-contrast head CT images without impacting workflow or storing protected health information (PHI).
- Received FDA 510(k) clearance and CE Mark approval.
Limitations
- The Accipio line of software has been discontinued by MaxQ AI.
- Not intended to be used as a stand-alone basis for clinical decision-making.
- Not intended to rule out hemorrhage or preclude clinical assessment of CT cases.
- MaxQ AI laid off sales and marketing teams associated with Accipio due to a change in focus.
- Algorithms designed to identify a specific clinical problem were considered only one part of a broader solution needed to impact patient outcomes.
Based on reviews from: MaxQ AI Receives FDA Clearance for Accipio Ixu2122 Intracranial Hemorrhage Platform, MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform | Imaging Technology News, FDA Clears Software Designed to Prioritize Non-Contrast Head CT Cases, MaxQ Al Ltd. August 7, 2020 Joshua Schulman, Ph.D. Vice President, Clinical, Regulatory and Quality Affairs 96 Yigal Alon S - accessdata.fda.gov, MaxQ discontinues Accipio AI software as firm switches gears | AuntMinnie
Last updated: 2026-07-22
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Accipiolx
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Accipiolx.
